Neuroblastoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• MYCN 0
• AKT 0
• TP53 0
• ALK 3
• B7-H3 7
• ERK 0
• PI3K 0
• MAPK 1
• SNCA 0
• mTOR 0
• NRF2 0
• NRAS 0
• AMPK 0
• BCL-2 0
• EZH2 0
• JNK 0
• KRAS 0
• MYC 0
• PPAR 0
• STAT3 0
• STING 1
• CDK4/6 0
• NTRK 0
• SIRT1 0
• CD19 3
• PARP 2
• RAS 1
• TDP-43 0
• VEGF 1
• BDNF 0
• HDAC 0
• HMGB1 0
• ROS1 1
• YAP 0
• BRAF 0
• FAK 0
• HIF-1 0
• IL-1 0
• IL-15 3
• MEK 0
• NLRP3 0
• PINK1 0
• PTEN 0
• APP 0
• BACE1 0
• CD47 0
• CGRP 0
• EGFR 1
• FGFR 0
• GPX4 0
• IDH 1
• IL-6 0
• MAPT 0
• MDM2 0
• PD-1 0
• PD-L1 0
• RET 0
• SOD1 0
• TFEB 0
• TNF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 31+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  NCT02650401· Hoffmann-La Roche· Source

• DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

  NCT05770037· Cancer Research UK· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 44
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 2
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 20
• Machine Learning 10
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

• Biomineralized SERS Nanotags Encode Biomolecular Identity into Machine Learning-Resolvable Fingerprints.

  ACS Appl Mater Interfaces, Sept 2026

• Artificial Intelligence for Diagnosis, Risk Stratification, and Prognosis of Neuroblastoma - A Systematic Review and Meta-Analysis.

  Curr Oncol Rep, Sept 2026

• Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study.

  Sci Rep, Aug 2026

• Application Value of a nomogram integrating contrast-enhanced CT radiomics and clinical indicators in evaluating lymph node metastasis in pediatric peripheral neuroblastoma.

  Cancer Imaging, May 2026

• Cell Analyser in Batch for Neurite (CABaNe), an Automated, High-Throughput ImageJ Macro for Cell and Neurite Analysis.

  eNeuro, Feb 2026

• Predicting neuroblastoma prognosis using machine learning analysis of metabolism-related gene network perturbation.

  BMC Pediatr, Jan 2026

• Multi-Omics Analysis Reveals the Molecular Subtypes and Confirmed the GREM1 as the Core Gene.

  J Gene Med, Jan 2026

• Eugenol as a Novel Neuroblastoma Therapeutic Identified by an Online Prognostic Assessment Platform.

  Front Biosci (Landmark Ed), Dec 2025

• Integrating machine learning and experiments to elucidate the potential molecular mechanisms of methylparaben-induced Alzheimer's disease: evidence from a Tau hyperphosphorylation cell model.

  BMC Neurol, Dec 2025

• An open-source screening platform accelerates discovery of drug combinations.

  Nat Commun, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.